Data / Drug companies / Somerset Therapeutics, LLC
Somerset Therapeutics, LLC: 188 products in the FDA NDC directory, labeler code 70069
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Somerset Therapeutics, LLC (labeler code 70069) lists 188 products in the FDA National Drug Code Directory, covering 83 finished drugs by generic name. By type: 186 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 25, 2026.
The request: Watch Somerset Therapeutics, LLC (FDA labeler code 70069): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70069
- Products in commercial distribution
- 188
- Packages
- 230
- Finished drugs by generic name
- 83
- Prescription products
- 186
- Over the counter products
- 2
- Controlled substance products
- Schedule III 1, Schedule IV 3, Schedule V 1
- Flagged as original packager
- 179 of 179 products that carry the flag
- Started marketing in the last 12 months
- 26
- Earliest marketing start
- December 11, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 188 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 186 | 98.9% |
| Over the counter drugs | 2 | 1.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 52 | 27.7% |
| Solution/ drops | 46 | 24.5% |
| Injection, solution | 37 | 19.7% |
| Solution | 18 | 9.6% |
| Tablet, film coated | 10 | 5.3% |
| Injection, powder, lyophilized, for solution | 5 | 2.7% |
| Injection, solution, concentrate | 4 | 2.1% |
| Tablet | 3 | 1.6% |
| Solution, concentrate | 2 | 1.1% |
| For solution | 2 | 1.1% |
| Capsule, delayed release | 2 | 1.1% |
| Solution, gel forming / drops | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Foscarnet Sodium | 70069-864 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
| Acetaminophen | 70069-871 | Injection, solution | Generic drugs (ANDA) | September 21, 2026 |
| Acamprosate calcium | 70069-860 | Tablet, delayed release | Generic drugs (ANDA) | August 10, 2026 |
| Sugammadex | 70069-893 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex | 70069-892 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Dalbavancin | 70069-830 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 27, 2026 |
| Isosulfan Blue | 70069-221 | Injection, solution | Generic drugs (ANDA) | June 30, 2026 |
| Carboprost tromethamine | 70069-825 | Injection, solution | Generic drugs (ANDA) | June 5, 2026 |
| Tofacitinib | 70069-842 | Tablet, film coated | Generic drugs (ANDA) | June 3, 2026 |
| Tofacitinib | 70069-841 | Tablet, film coated | Generic drugs (ANDA) | June 3, 2026 |
| Nicardipine Hydrochloride | 70069-876 | Injection | Generic drugs (ANDA) | April 20, 2026 |
| Nicardipine Hydrochloride | 70069-875 | Injection | Generic drugs (ANDA) | April 20, 2026 |
| Levetiracetam | 70069-847 | Injection | Generic drugs (ANDA) | April 20, 2026 |
| Levetiracetam | 70069-846 | Injection | Generic drugs (ANDA) | April 20, 2026 |
| Levetiracetam | 70069-845 | Injection | Generic drugs (ANDA) | April 20, 2026 |
| Milrinone Lactate in 5% Dextrose | 70069-873 | Injection, solution | Generic drugs (ANDA) | March 25, 2026 |
| Milrinone Lactate in 5% Dextrose | 70069-872 | Injection, solution | Generic drugs (ANDA) | March 25, 2026 |
| Dihydroergotamine mesylate | 70069-880 | Spray, metered | Generic drugs (ANDA) | March 24, 2026 |
| Sacubitril and Valsartan | 70069-855 | Tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| Sacubitril and Valsartan | 70069-854 | Tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| Sacubitril and Valsartan | 70069-853 | Tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| Rilpivirine | 70069-848 | Tablet, film coated | Generic drugs (ANDA) | January 30, 2026 |
| Eltrombopag olamine | 70069-840 | Tablet, film coated | Generic drugs (ANDA) | January 14, 2026 |
| Eltrombopag olamine | 70069-839 | Tablet, film coated | Generic drugs (ANDA) | January 14, 2026 |
| Eltrombopag olamine | 70069-838 | Tablet, film coated | Generic drugs (ANDA) | January 14, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.